JPX · 4524.T
Morishita Jintan Co., Ltd.
¥2,195-¥23 (-1.04%)
Morishita Jintan Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 8.16% below the high.
Loading market information…
JPX · 4597.T · JPY
Stock price, earnings
Quote as of Oct 30, 2026, 06:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · JPY. Historical prices are not a forecast.
Solasia Pharma K.K.’s quoted price sits in the lower half of its reported 52-week range, 35.71% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Solasia Pharma K.K.’s next earnings report is currently expected on Nov 12, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Solasia Pharma K.K.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Established in 2006 and headquartered in Tokyo, Japan, Solasia Pharma K.K. is dedicated to the development and commercialization of oncology treatments throughout Japan and other parts of Asia. The company's marketed products include SP-03 (episil oral liquid), designed for the protection and relief of oral pain and inflammation (mucositis/stomatitis) resulting from cancer chemotherapy and radiation. Additionally, they offer SP-01 (Sancuso), a transdermal patch that delivers granisetron, an anti-emetic, into the bloodstream to manage chemotherapy-induced nausea and vomiting. Solasia Pharma's development pipeline features SP-02 (Darinaparsin), a mitochondrial-targeted agent that has successfully completed Phase III clinical trials for a range of hematologic and solid cancers. Also in Phase III clinical study is SP-05 (Arfolitixorin), which aims to bolster the anti-tumor effectiveness of fluorouracil in various cancers, including pancreatic, breast, stomach, and head and neck cancers. In its pre-clinical stage, SP-04 is being developed to address chemotherapy-induced peripheral neuropathy.
Latest available per-share figures in JPY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:18 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
¥2,195-¥23 (-1.04%)
Morishita Jintan Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 8.16% below the high.
¥700+¥2 (+0.29%)
Data Horizon Corporation’s quoted price sits in the upper half of its reported 52-week range, 6.29% below the high.
¥18+¥1 (+5.88%)
OncoTherapy Science, Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.06% below the high.
¥89-¥3 (-3.26%)
Chiome Bioscience Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.56% below the high.
¥800-¥1 (-0.12%)
ADR120S, Inc.’s quoted price sits in the lower half of its reported 52-week range, 10.11% below the high.
¥40-¥1 (-2.44%)
BrightPath Biotherapeutics Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 58.33% below the high.
¥49-¥1 (-2.0%)
Chordia Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.63% below the high.
¥47-¥1 (-2.08%)
MedRx Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 65.44% below the high.
